Showing results (451-460 of 470) with videos related to
Sort By:
Pageof 47
Science Advances|March 2, 2022
Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumorsAmanda M Nash, Maria I Jarvis, Samira Aghlara-Fotovat, et al.Obesity (Silver Spring, Md.)|February 7, 2023
A two-decade population-based study on the effect of hypertension in the general population with obesity in the United StatesGwyneth Kong, Yip H Chin, Jieyu Lim, et al.Annals of Clinical and Translational Neurology|July 29, 2024
The clinical relevance of MOG antibody testing in cerebrospinal fluidMolly Reynolds, Irene Tan, Kristy Nguyen, et al.Heart Rhythm|June 5, 2025
Prolonged hospitalization after catheter ablation of ventricular tachycardia: Predictors and outcomesTess Calcagno, Andrew Cesmat, Joseph Sipko, et al.Journal of Clinical Immunology|July 5, 2023
Infection and Vaccine Induced Spike Antibody Responses Against SARS-CoV-2 Variants of Concern in COVID-19-Naïve Children and AdultsAleha Pillay, Avani Yeola, Fiona Tea, et al.Circulation|October 20, 2017
Mortality and Cerebrovascular Events After Heart Rhythm Disorder Management ProceduresJustin Z Lee, Jayna Ling, Nancy N Diehl, et al.Journal of Cardiovascular Electrophysiology|June 9, 2026
Invasive Assessment of Right Ventricular Dysfunction Predicts Periprocedural Outcomes in Patients Undergoing Unplanned Ventricular Tachycardia AblationTess Calcagno, Sai Prasad Ramachandran, V Karthik, et al.Journal of Cardiovascular Electrophysiology|September 16, 2025
Catheter Ablation for Ventricular Tachycardia in Ischemic Cardiomyopathy: A Meta-Analysis With Reconstructed Time-to-Event and Trial Sequential AnalysisHossam Elbenawi, Youmna Ayman, Ahmed Hashim, et al.Heart Rhythm|January 19, 2019
Stroke in patients with cardiovascular implantable electronic device infection undergoing transvenous lead removalJustin Z Lee, Pradyumna Agasthi, Ahmed K Pasha, et al.Oncoimmunology|May 1, 2023
Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanomaJorge D Oldan, Benjamin C Giglio, Eric Smith, et al.Pageof 47